RENBIO

Serial Number 90309237
Registration 7671681
700

Registration Progress

Application Filed
Nov 10, 2020
Under Examination
Jan 4, 2022
Approved for Publication
Nov 9, 2021
Published for Opposition
Nov 9, 2021
Registered
Jan 28, 2025

Trademark Image

RENBIO

Basic Information

Serial Number
90309237
Registration Number
7671681
Filing Date
November 10, 2020
Registration Date
January 28, 2025
Published for Opposition
November 9, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 28, 2025
Registration
Registered
Classes
001 005 010

Rights Holder

RENBIO, INC.

03
Address
30-02 48TH AVENUE
LONG ISLAND CITY, NY 11101

Ownership History

RenBio, Inc.

Original Applicant
03
Long Island City, NY

RenBio, Inc.

Owner at Publication
03
Long Island City, NY

RENBIO, INC.

New Owner After Publication #1
03
LONG ISLAND CITY, NY

RENBIO, INC.

Original Registrant
03
LONG ISLAND CITY, NY

Legal Representation

Attorney
Rachelle A. Dubow, Esq.

USPTO Deadlines

Next Deadline
2008 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-01-28)
Due Date
January 28, 2031
Grace Period Ends
July 28, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

50 events
Date Code Type Description Documents
Jan 28, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 28, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 8, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jan 8, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jan 7, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 3, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Dec 18, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 18, 2024 IUAF S USE AMENDMENT FILED Loading...
Sep 13, 2024 NOAC E CORRECTED NOA E-MAILED Loading...
Jul 2, 2024 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 2, 2024 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jul 2, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 2, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 28, 2024 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Jun 28, 2024 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Jun 27, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 20, 2024 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Dec 12, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 8, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 8, 2023 EX4G S SOU EXTENSION 4 GRANTED Loading...
Dec 8, 2023 EXT4 S SOU EXTENSION 4 FILED Loading...
Jun 22, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 20, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jun 20, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
Jun 20, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 5, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 3, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jan 3, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Jan 3, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 5, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 1, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 1, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 1, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 19, 2022 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Jan 4, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 9, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 9, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 20, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 7, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 6, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 5, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 5, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 9, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Sep 9, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Sep 9, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 5, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 5, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 5, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 2, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 001
Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; Biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals
First Use Anywhere: Nov 7, 2024
First Use in Commerce: Nov 7, 2024
Class 005
Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; Pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Nucleic acid sequences for medical purposes; Pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals
First Use Anywhere: Nov 7, 2024
First Use in Commerce: Nov 7, 2024
Class 010
Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems being pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs; medical devices, namely, pulse and waveform generators for electroporation mediated administration of drugs to humans and animals; delivery systems comprised of pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices comprised of pulse and waveform generators using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices comprised of pulse and waveform generators for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals
First Use Anywhere: 20231200
First Use in Commerce: 20231200

Classification

International Classes
001 005 010